Description
Cancer Markers
Cancer Markers contains revenue assessment, analysis, and competitive review for tests for oncology using biomarkers. Multiple firms manufacture a range of technologies – histology/cytology, immunohistochemistry, in situ hybridization, immunoassays – tumor markers, flow cytometry, rapid tests, and molecular marker-based technologies – to determine risk for cancer, screen for cancer, test for cancer, and help in prognosis and personalization of therapy.
Cancer Markers provides the following information: global cancer biomarkers diagnostic revenues, 2015 and 2020 (IHC, ISH, immunoassays, flow, rapid, molecular); global cancer biomarkers diagnostic market percentage (IHC, ISH, flow cytometry, molecular-based assays, NMP22, FOB, PSA, CEA, CA125, AFP, other tumor markers); selected extensively used tumor markers; selected biomarkers and biomarker panels to determine risk of cancer, and manufacturers developing/marketing these biomarkers; selected biomarkers and biomarker panels for cancer screening, and manufacturers developing/marketing these biomarkers; selected biomarkers and biomarker panels for diagnosis and/or monitoring of cancer, and manufacturers developing/marketing these biomarkers; selected biomarkers and biomarker panels to predict prognosis of cancer, and manufacturers developing/marketing these biomarkers; selected biomarkers and biomarker panels to predict response to therapy, and manufacturers developing/marketing these biomarkers; selected FDA-cleared/approved companion diagnostic tests, and manufacturers developing/marketing these biomarkers; selected manufacturers developing/marketing cancer tests; common next generation molecular test traits; selected sample preparation reagents; and selected cancer test innovations, 2015. Abbott Laboratories, Alere Inc., bioMérieux SA, Hologic, Inc., Illumina, Inc., QIAGEN N.V., Roche, and Thermo Fisher Scientific, Inc. are among the manufacturers discussed in the competitive analysis.
Table of Contents
ONE: EXECUTIVE SUMMARY
Market
Scope and Methodology
TWO: INTRODUCTION
Cancer Risk Assessment
Cancer Screening
Cancer Monitoring
Cancer Prognosis Assessment
Personalized Medicine/Precision Testing
Competition in Cancer Biomarkers
Molecular Markers
Precision Medicine
THREE: CANCER MARKERS MARKET ANALYSIS
FOUR: COMPANY PROFILES
20/20 GeneSystems, Inc
Abbott Laboratories
Recent Revenue History
Agreements
Abcodia Ltd.
Financings
Alere Inc. (Abbott)
Ambry Genetics Corp.
Asuragen, Inc.
Diagnostic Products
Translational/Companion Diagnostics
Agreements
Athena Diagnostics, Inc. (A Quest Diagnostics Business)
bioMérieux SA
Recent Revenue History
Company Overview
Immunodiagnostics for Lab Professionals (Clinical Laboratories)
Molecular Diagnostics
bioTheranostics, Inc. (A bioMérieux Company)
Cancer Genetics, Inc.
Recent Revenue History
Company Overview
Agreements
Genomic Health, Inc.
Recent Revenue History
Genoptix (A Novartis Company)
Hologic, Inc.
Recent Revenue History
Company Overview
Illumina, Inc.
Recent Revenue History
Company Overview
Myriad Genetics, Inc.
Recent Revenue History
Company Overview
QIAGEN N.V.
Recent Revenue History
Roche
Recent Revenue History
Company Overview
Roche Professional Diagnostics
Molecular Diagnostics
Tissue Diagnostics
Thermo Fisher Scientific, Inc.
Recent Revenue History
Company Overview
Wako Pure Chemical Industries, Ltd.,
LIST OF EXHIBITS
ONE: EXECUTIVE SUMMARY
Figure 1-1: Cases of Cancer by Type
Figure 1-2: Cancer Marker-Based Test Market, 2015 and 2020
TWO: INTRODUCTION
Table 2-1: Estimated Global Incidence and Mortality due to Cancer, 2012 – By Regionsnof the World
Table 2-2: Selected Widely Used Tumor Markers
Table 2-3: Selected Biomarkers and Biomarker Panels to Assess Risk of Cancer, and Companies Developing/Marketing These Biomarkers
Table 2-4: Selected Biomarkers and Biomarker Panels for Cancer Screening, and Companies Developing/Marketing These Biomarkers
Table 2-5: Selected Biomarkers and Biomarker Panels for Diagnosis and/or Monitoring of Cancer, and Companies Developing/Marketing These Biomarkers
Table 2-6: Selected Biomarkers and Biomarker Panels to Predict Prognosis of Cancer,and Companies Developing/Marketing These Biomarkers
Table 2-7: Selected Biomarkers and Biomarker Panels to Predict Response to Therapy,and Companies Developing/Marketing These Biomarkers
Table 2-8: Selected FDA Cleared/Approved Companion Diagnostic Tests, and Companies Developing/Marketing These Biomarkers
Table 2-9: Selected Companies Developing/Marketing Cancer Tests
Table 2-10: Common Next Generation Molecular Test Traits
Table 2-11: Selected Sample Preparation Reagents
Table 2-12: Selected Cancer Test Innovations, 2015
THREE: CANCER MARKERS MARKET ANALYSIS
Table 3-1: Worldwide Cancer Biomarkers Diagnostic Market – 2015 and 2020 (IHC,ISH, Immunoassays, Flow, Rapid, Molecular)
Table 3-2: Selected International Agreements
Figure 3-1: Worldwide Cancer Biomarkers Diagnostic Market Percentage (IHC, ISH,Flow Cytometry, Molecular-Based Assays, NMP22, FOB, PSA, CEA, CA125, AFP,Other Tumor Markers)
